The exchanges set up by the health reform law have rebounded, largely thanks to the efforts of UnitedHealth Group’s Optum Insights unit, which has made using the federal exchange websites much easier. A number of state exchanges are still struggling. (WSJ Article) Enrollment, the Administration claims, is over 4 million, but the reality is many of those people have not actually paid for coverage yet. The actual number is probably 3.5 million at most. This is far below the Administration’s and the Congressional Budget Office’s projections. Another reality is that younger, healthier people are not enrolling in the numbers needed to create a sound actuarial pool for participating insurers. UnitedHealth, the savior of the federal exchange functionality, also looks pretty smart for not participating as a plan on those exchanges. And it has become apparent that the administration has eviscerated its own individual mandate through a broad and ambiguous “hardship” definition and other loopholes. Young people are smart and word gets around quickly in the age of social media, so don’t expect them to feel pressured to sign up. Many of the people who did sign up will get subsidies and Medicaid enrollment has boomed, so the federal and ultimately the states’ deficits will also be growing more rapidly. It is not an exaggeration to describe reform, as many predicted, as a disaster, a very expensive disaster which has upended many lives. And the worst may be yet to come when the plans offered on the exchanges have to set premiums for the second year of coverage. And of course, we still don’t have the employer mandate in place.
If you are wondering about the sanity of the market, wonder no more. Castlight came public at $16 a share and popped to over $40 a share. This for a company with $13 million in revenue and tens of millions of dollars in accumulated losses. And in a market with no barriers to entry and no proprietary value. Transparency and decision support will be, no, are, delivered free by a number of organizations. What are supposedly smart investors thinking? I suspect we will see a number of acquisitions made by Castlight to prop up a very bad business model. And we will see every other "transparency" or similar health care company try to go public.
http://medcitynews.com/2014/03/castlight-health-ipo-pos-as-market-supports-tools-to-cut-healthcare-costs-powered-hype-hope/?utm_source=MedCity+News+Subscribers&utm_campaign=48b6d81e91-RSS_EMAIL_CAMPAIGN&utm_medium=email&utm_term=0_c05cce483a-48b6d81e91-67648197Mark Farrah Associates issues its most recent update on large health plan company enrollment and profitability.
Read More
The cost of whole genome sequencing is coming down, but cost, reproducibility, translation and process issues make its routine use for clinical practice unlikely without further refinement and knowledge growth.
Read More
Validic has raised $1.2 million for its software designed to help retrieve data from patient wearable devices and other sources.
http://medcitynews.com/2014/03/validic-expands-management-team-raises-1-25m/?utm_source=MedCity+News+Subscribers&utm_campaign=7a09f849e6-RSS_EMAIL_CAMPAIGN&utm_medium=email&utm_term=0_c05cce483a-7a09f849e6-67648197The 2015 Medicare Advantage and Part D Advance Notice and draft Call Letter provide some interesting insights into CMS' views on various topics, as well as reimbursements for those program…
Read More
In a bid to expand its wellness business, Quest Labs is buying Summit Health, which provides onsite screening services, primarily for employers.
http://www.modernhealthcare.com/article/20140311/NEWS/303119942?AllowView=VDl3UXk1TzZDL1dCbkJiYkY0M3hlMENvamtVZER1UT0=&utm_source=link-20140311-NEWS-303119942&utm_medium=email&utm_campaign=mpdaily&utm_name=top#Nextimage, which provides radiology management services primarily for workers' compensation, has acquired WorkWell, which offers services related to prevention of soft-tissue and musculoskeletal injuries.
http://www.pehub.com/2014/03/chrysalis-ventures-backed-nextimage-completes-workwell-acquisition/The annual Pharmacy Benefit Management Institute Specialty Drug Benefit Report highlights trends in this growing category of drugs.
Read More
